The Role of Dopaminergic Systems in the Perinatal Sensitivity to 3,4-Methylenedioxymethamphetamine-lnduced Neurotoxicity in Rats1

Journal of Pharmacology and Experimental Therapeutics

Volumn 286, Issue 3, 1998, Pages 1159-1165

  Aguirre, Norberto ^a   Barrionuevo, Meritxell ^a   Lasheras, Berta ^a   Del Rio, Joaquin ^a,b  

^a I Iniversitv nf Navftm ^*  (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; 4-IODO-2,5-DIMETHOXYPHENYLISOPROPYLAMINE; AMPHETAMINE DERIVATIVE; CARRIER PROTEIN; DOPAMINE; LEVODOPA; MEMBRANE PROTEIN; NERVE PROTEIN; SEROTONIN; SEROTONIN RECEPTOR; SEROTONIN TRANSPORTER; SLC6A4 PROTEIN, RAT; BENSERAZIDE; DESIPRAMINE; OXIDOPAMINE; PAROXETINE;

AGE; ANIMAL; ARTICLE; BODY TEMPERATURE; BRAIN; DRUG EFFECT; FEMALE; PHYSIOLOGY; RAT; WISTAR RAT; ANIMAL MODEL; ANIMAL TISSUE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG DETERMINATION; FRONTAL CORTEX; HIPPOCAMPUS; HYPERTHERMIA; NEUROTOXICITY; NONHUMAN; PATHOGENESIS; PERINATAL DRUG EXPOSURE; PREGNANCY; PRIORITY JOURNAL; SEROTONIN BRAIN LEVEL; SUBCUTANEOUS DRUG ADMINISTRATION; TEMPERATURE MEASUREMENT; THERMOGENESIS;

AGE FACTORS; AMPHETAMINES; ANIMALS; BODY TEMPERATURE; BRAIN; CARRIER PROTEINS; DOPAMINE; FEMALE; LEVODOPA; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NERVE TISSUE PROTEINS; RATS; RATS, WISTAR; RECEPTORS, SEROTONIN; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 0032161183     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Aguirre N, Galbete JL, Lasheras B and Del Rio J (1995) Methylenedioxymethamphetamine induces opposite changes in central pre- and postsynaptic 5-HT1A receptors in rats. Eur J Pharmacol 281:101-105.
2. Aguirre N, Galbete JL, Lasheras B and Del Rio J (1995) Methylenedioxymethamphetamine induces opposite changes in central pre- and postsynaptic 5-HT1A receptors in rats. Eur J Pharmacol 281:101-105.
3. Battaglia G, Yeh SY, O'Hearn E, Molliver ME, Kuhar MJ and De Souza EB (1987) 3,4-Methylenedioxymethamphetamine and 3,4-Methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3Hjparoxetine-labeled serotonin uptake sites. J Pharmacol Exp Ther 242:911-916.
4. Broening HW, Bacon L and Slikker Jr W ( 1994) Age modulates the long-term but not the acute effects of the serotonergic neurotoxicant 3,4-methylenedioxymethamphetamine. J Pharmacol Exp Ther 271:285-293.
5. Broening HW, Bowyer JF and Slikker Jr W ( 1995) Age-dependent sensitivity of rats to the long-term effects of the serotonergic neurotoxin (±)-3,4-methylenedioxymethamphetamine (MDMA) correlates with the magnitude of the MDMA-induced thermal response. J Pharmacol Exp Ther 275:325-333.
6. Bruinink A, Lichtensteiger W and Schlumpf M ( 1983) Pre- and postnatal ontogeny and characterization of dopaminergic D2, serotonergic S2, and spirodecanone binding sites in rat forebrain. J Neurochem 40:1227-1236.
7. Cadet JL, Ladenheim B, Hirata H, Rothman RB, Ali S, Carlson E, Epstein C and Moran TH ( 1995) Superoxide radicals mediate the biochemical effects of methylenedioxymethamphetamine (MDMA): Evidence from using CuZn-superoxide dismutase transgenic mice. Synapse 21:169-176.
8. Cheronis JC, Erinoff L, Heller A and Hoffmann PC (1979) Pharmacological analysis of the functional ontogeny of the nigrostriatal dopaminergic neurons. Brain Res 169:545-560.
9. Colado MI and Green AR (1994) A study on the mechanism of MDMA (Ecstasy)induced neurotoxicity of 5-HT neurones using chlormethiazole, dizocilpine and other protective compounds. Br J Pharmacol 111:131-136.
10. Colado MI and Green AR (1995) The spin trap reagent a-phenil-N-tertbutyl nitrone prevents ecstasy-induced neurodegeneration of 5-hydroxytryptamine neurons. Eur J Pharmacol 28:343-346.
11. Colado MI, O'Shea E, Granados R, Misra A, Murray TK and Green AR (1997) A study of the neurotoxic effect of MDMA (ecstasy) on 5-HT neurones in the brains of mothers and neonates following administration of the drug during pregnancy. Br J Pharmacol 121:827-833.
12. Erinoff L and Heller A (1978) Functional ontogeny of nigrostriatal neurons. Brain Res 142:566-569.
13. Faraj BA, Olkowski ZL and Jackson RT (1994) Active [fiH]-dopamine uptake by human lymphocites: Correlates with serotonin transporter activity. Pharmacol 48:320-327.
14. Gordon CJ (1990) Thermal biology of the laboratory rat. Physiol Behau 47:962-991.
15. Gudelsky GA and Nash JF (1996) Carrier-mediated release of serotonin by 3,4methylenedioxymethamphetamine: Implications for serotonin-dopamine interactions. J Neurochem 66:243-249.
16. Gudelsky GA and Yamamoto BK (1994) MDMA increases the extracellular concentration of 2,3-dihydroxybenzoic acid in the striatum: Evidence for increased hydroxyl radical formation. Soc Neurosci Abstr 24:419.1.
17. Gudelsky GA, Yamamoto BK and Nash JF (1994) Potentiation of 3,4-methylenedioxymethamphetamine-induced dopamine release and serotonin neurotoxicity by 5-HT2 agonists. Eur J Pharmacol 264:325-330.
18. Gudelsky GA (1996) Effect of ascorbate and cysteine on the 3,4-methylenedioxymethamphetamine-induced depletion of brain serotonin. J Neural Transm 103:1397-1404.
19. Huang X and Nichols DE (1993) 5-HT2 receptor-mediated potenciation of dopamine synthesis and central serotonergic deficits. Eur J Pharmacol 238:291-296.
20. Johnson MP and Nichols DE (1991) Combined administration of a non neurotoxic 3,4-methylenedioxymethamphetamine analogue with amphetamine produces serotonin neurotoxicity in rats. Neuropharmacology 30:819-822.
21. Kirksey DF and Slotkin TA (1979) Concomitant development of (3HJ-dopamine and [3H]-5-hydroxytryptamine uptake systems in rat brain regions. Br J Pharmacol 67:387-391.
22. Koch S and Galloway MP (1997) MDMA induced dopamine release in vivo: role of endogenous serotonin. J Neural Transm 104:135-146.
23. Kostrzewa RM and Jacobowitz DM (1974) Pharmacological actions of 6-hydroxydopamine. Pharmacol Rev 26:199-288.
24. Malberg JE, Sabol KE and Seiden LS (1996) Co-administration of MDMA with drugs that protect against MDMA neurotoxicity produces different effects on body temperature in the rat. J Pharmacol Exp Ther 278:258-267.
25. Marcusson JO, Bergström M, Eriksson K and Ross SB (1988) Characterization of [3H]paroxetine binding in rat brain. J Neurochem 50:1783-1790.
26. Morilak DA and Ciaranello RD (1993) Ontogeny of 5-Hydroxytryptamine2 receptor immunoreactivity in the developing rat brain. Neuroscience 55:869-880.
27. Nash JF and Brodkin J (1991) Microdialysis studies on 3,4- methylenedioxymetham- phetamine-induced dopamine release: effect of dopamine uptake inhibitors. J Pharmacol Exp Ther 259:820-825.
28. Nash JF and Nichols DE (1991) Microdialysis studies of 3,4-methyelendioxymethamphetamine and structurally related analogues. Eur J Pharmacol 200:53-58.
29. Nash JF, Meltzer HY and Gudelsky GA (1990) Effect of 3,4-methylenedioxymethamphetamine on 3,4-dihydroxyphenylalanine accumulation in the striatum and nucleus accumbens. J Neureichem 54:1062-1067.
30. Nash JF (1990) Ketanserin pretreatment attenuates MDMA-induced dopamine release in the striatum as measured by in vivo microdialysis. Life Set 47:2401-2408.
31. Nomura Y, Naitoh F and Segawa T (1976) Regional changes in monoamine content and uptake of the rat brain during postnatal development. Brain Res 101:305-315.
32. O'Hearn E, Battaglia G, De Souza EB, Kuhar MJ and Molliver ME (1988) Methylenedioxyamphetamine (MDA) and Methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: Inmunocytochemical evidence for neurotoxicity. J Neurosci 8:2788-2803.
33. Pérez-Otano I, Herrero MT, Oset C, De Ceballos ML, Luquin MR, Obeso JA and Del Rio J (1991) Extensive loss of brain dopamine and serotonin induced by chronic administration of MPTP in the marmoset. Brain Res 567:127-132.
34. Perry KW, Kostrzewa RM and Fuller RW ( 1995) Persistence of long-lasting serotonin depletion by p-chloroamphetamine in rat brain after 6-hydroxydopamine lesioning of dopamine neurons. Biochem Pharmacol 50:1305-1307.
35. Roth BL, Hamblin MW and Ciaranello RD (1991) Developmental regulation of 5-HT2 and 5-HTlc mRNA and receptor levels. Dev Brain Res 58:51-58.
36. Schmidt CJ and Lovenberg W (1985) In vitro demonstration of DA uptake by neostriatal serotonergic neurons of the rat. Neurosci Lett 59:9-14.
37. Schmidt CJ and Taylor VL (1987) Depression of rat brain tryptophan hydroxylase following the acute administration of methylenedioxymethamphetamine. Biochem Pharmacol 36:4095-4102.
38. Schmidt CJ, Abbate GM, Black CK and Taylor VL (1990a) Selective 5-hydroxytryptamine2 receptor antagonist protect against the neurotoxicity of methylenedioxymethamphetamine in rats. J Pharmacol Exp Ther 255:478-483.
39. Schmidt CJ, Black CK and Taylor VL (1990b) Antagonism of the neurotoxicity due to a single administration of methylenedioxymethamphetamine. Eur J Pharmacol 181:59-70.
40. Schmidt CJ, Black CK and Taylor VL ( 1991a) L-DOPA potentiation of the serotonergic deficits due to a single administration of 3,4-methylenedioxymethamphetamine, pchloroamphetamine or methamphetamine to rats. Eur J Pharmacol 203:41-49.
41. Schmidt CJ, Black CK, Taylor VL, Fadayel GM, Humphreys TM, Nieduzak TR and Sorensen SM (1992a) The 5-HT2 receptor antagonist, MDL 28,133A, disrupts the serotonergic-dopaminergic interaction mediating the neurochemical effects of 3,4methylenedioxymethamphetamine. Eur J Pharmacol 220:151-159.
42. Schmidt CJ, Fadayel GM, Sullivan CK and Taylor VL (1992b) 5-HT2 receptors exert a state-dependent regulation of dopaminergic function: studies with MDL 100,907 and the amphetamine analogue 3,4-methylenedioxymethamphetamine. Eur J Pharmacol 223:65-74.
43. Schmidt CJ, Sullivan CK and Fadayel GM (1994) Blockade of striatal 5-hydroxy tryptamine2 receptors reduces the increase in extracellular concentrations of dopamine produced by the amphetamine analogue 3,4-methylenedioxymethamphetamine. J Neurochem 62:1382-1389.
44. Schmidt CJ, Taylor VL, Abbate GM and Nieduzak TR (1991b) 5-HT2 antagonists stereoselectively prevent the neurotoxicity of 3,4-methylenedioxymethamphetamine by blocking the acute stimulation of dopamine synthesis: reversal by LDopa. J Pharmacol Exp Ther 256:230-235.
45. Schmidt CJ (1987) Neurotoxicity of the psychedelic amphetamine methylenedioxymethamphetamine. J Pharmacol Exp Ther 240:1-7.
46. Slikker W Jr, Ali SF, Scallet AC, Frith CH, Newport GD and Bailey JR (1988) Neurochemical and neurohistological alterations in the rat and monkey produced by orally administered methylenedioxymethamphetamine (MDMA). Toxicol Appl Pharmacol 94:448-457.
47. Sprague JE and Nichols DE (1995a) Inhibition of MAO-B protects against MDMAinduced neurotoxicity in the striatum. Psychopharmacology 118:357-359.
48. Sprague JE and Nichols DE ( 1995b) The Monoamine Oxidase-B inhibitor L-Deprenyl protects against 3,4-methylenedioxymethamphetamine-induced lipid peroxidation and long-term serotonergic deficits. J Pharmacol Exp Ther 273:667-673.
49. Sprague JE, Huang X, Kanthasamy A and Nichols DE ( 1994) Attenuation of 3.4methylenedioxymethamphetamine (MDMA) induced neurotoxicity with the serotonin precursors tryptophan and 5-hydroxytryptophan. Life Sei 55:1193-1198.
50. Sprague JE, Johnson MP, Schmidt CJ and Nichols DE (1996) Studies on the mechanism of p-chloroamphetamine neurotoxicity. Biochem Pharmacol 52:1271-1277.
51. St. Omer VEV, Ali SF, Holson RR, Duhart HM, Scalzo FM and Slikker W Jr (1991I Behavioral and neurochemical effects of prenatal methylenedioxymethamphetamine (MDMA) exposure in rats. Neurobehau Toxicol Teratol 13:13-20.
52. Stone DM, Johnson M, Hanson GR and Gibb JW (1988) Role of endogenous dopa mine in the central serotonergic deficits induced by 3,4-methylenedioxymethamphetamine. J Pharmacol Exp Ther 247:79-87.
53. Stone DM, Stahl DC, Hanson GR and Gibb JW (1986) The effects of 3,4Methylenedioxymethamphetamine (MDMA) and methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain. Eur J Pharmacol 128:41-48.
54. White SR, Obradovic T, Imel KM and Wheaton MJ (1996) The effects of methylenedioxymethamphetamine (MDMA, ecstasy) on monoaminergic neurotransmission in the central nervous system. Progr Neurobiol 49:455-479.
55. Zifa E and Pillion G (1992) 5-Hydroxytryptamine receptors. Pharmacol Rev 44:401-458.